Dr. Daniel Cameron

When Patients Know More Than Doctors Guest Blog By Jennifer Bybel Lown, Nurse Practitioner Dr. Daniel Cameron & Associates Lyme disease patient advocacy has become an essential part of care, especially when the illness is misunderstood or misdiagnosed. In many cases, patients and their families become the most informed voices in the diagnostic process. Patients […]

Borrelia miyamotoi FDA Test: Why the Diagnostic Gap Matters The FDA Testing Gap for Emerging Tick-Borne Diseases There is currently no FDA-approved test for Borrelia miyamotoi. This gap highlights a larger problem in diagnostic medicine: emerging tick-borne infections are being identified faster than regulatory pathways can support testing. :contentReference[oaicite:0]{index=0} If testing were limited only to

Lyme Disease Treatment: Why One Size Does Not Fit All Lyme disease individualized treatment is essential because patients vary widely in symptoms, response to therapy, and clinical course. A uniform approach may not address the complexity of this infection. A review of the International Lyme and Associated Diseases Society (ILADS) 2014 evidence-based guidelines highlights this

Fibromyalgia vs Lyme Disease: Could Infection Be Missed? Fibromyalgia vs Lyme disease is a critical diagnostic challenge, as both conditions share overlapping symptoms that can lead to missed or delayed diagnosis. After decades of treating Lyme disease, I have seen patients initially diagnosed with fibromyalgia improve when underlying infection is addressed. This overlap raises an

The task force by Executive Order must submit an action plan by February 15, 2015, outlining specific steps on how to implement a national strategy to combat antibiotic resistance and accelerate research and development on new antibiotics by 2020. The task force will be led by the secretaries of Health and Human Services, the Department

Antibiotic Resistance Policy: Impact on Lyme Disease Treatment Efforts to combat antibiotic resistance are essential—but they may have unintended consequences for patients with Lyme disease. The federal task force established by Executive Order was charged with developing a national strategy to address antibiotic resistance and accelerate the development of new treatments. The task force includes

Antibiotic Resistance Policy: Impact on Lyme Disease Treatment Efforts to combat antibiotic resistance are essential—but they may have unintended consequences for patients with Lyme disease. The federal task force established by Executive Order was charged with developing a national strategy to address antibiotic resistance and accelerate the development of new treatments. The task force includes

Lyme Disease in Ohio: Growing Risk Beyond Endemic Areas Lyme disease Ohio risk is increasing as black-legged ticks continue to expand across the state. This trend challenges the long-standing belief that Lyme disease is limited to traditionally endemic regions. Deer tick distribution in Ohio (Glenn Needham) Over a five-year period, researchers from Ohio State University

LLyme disease patients may struggle with depression Lyme disease depression symptoms are more common than many realize—and often misunderstood. In patients with chronic neurologic Lyme disease, depression frequently occurs alongside fatigue, headaches, cognitive difficulties, and joint pain. One study found that more than one-third of patients with chronic neurologic Lyme disease experienced depression in addition

LabCorp Western Blot Policy: What Changed and Why It Matters The LabCorp Western blot Lyme test policy change highlights a critical issue in Lyme disease diagnosis: access to testing and its limitations. :contentReference[oaicite:1]{index=1} When LabCorp Restricted Western Blot Access In 2014, LabCorp announced a policy change that sent shockwaves through the Lyme disease community: physicians